Nothing found.

Nothing found.

cor-por-ra-del-ic (adj): manifesting corporate structures, ethos, or logic within the context of the psychedelic landscape.

cor-por-ra-de-lia (n.): the world of people, phenomena, or items associated with corporadelic entities.

The term “corporadelic” was initially coined independently and simultaneously by Dr. Katherine MacLean (a former lead researcher and session guide for psilocybin research at Johns Hopkins University School of Medicine) and Brett Greene (co-founder emeritus of Psymposia and founder of psychedelic pharmaceutical company, Adelia Therapeutics) in 2019. Dr. MacLean defined the term as, “manifesting corporations to commodify psychedelic experiences.”

Amidst Pandemic, Psychedelic Investor Christian Angermayer Can’t Imagine Life Beyond Capitalism


As the coronavirus pandemic rages on, Christian Angermayer, the world’s largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences, calls to sacrifice public health for the sake of “the economy.”

“Flattening The Curve is Complete BS”: Pandemic Advice From Psychedelic Investor Christian Angermayer


In response to the coronavirus pandemic, Christian Angermayer—the world's largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences—dismisses medical experts in his desperation to reboot the economy.

Dear Psychedelic Researchers


The coronavirus has made it clear that psychedelic medicalization will not revolutionize mental healthcare without systemic socioeconomic change.

Calm Down. What’s the Worst Thing That the Wellness Industry Could Do to Psychedelics?


As technology and psychedelics turn to mental health, we’ll likely see a future where we are treated based on our digital biomarkers, and sold mental health services based on the personal data we surrender.

Talking Psychedelic Capitalism in a WeWork Ballroom


Psychedelic capitalists justify their decision to go for-profit in the ballroom of America’s most recent for-profit flop.

Christian Angermayer’s ATAI Life Sciences is positioned to take the psychedelic throne from MAPS


After decades of psychedelic nonprofits paving regulatory pathways and priming wealthy investors, for-profits are moving in to reap the rewards.

“Making psychedelics boring again”— Unless you’re a privileged psychedelic executive, of course


The new leaders of the psychedelic medicalization industry seem to see themselves as above their own self-proposed rules.

Psychedelic Trade Secrets and Get-Rich-Quick Schemes —a Benefit to Investors, a Harm to Progress


“Play the field right and there’s money to be made even off some of the shit companies purely based on the wave.”

Never Forget: Before There Was A Mush Rush, There Was A Plea For Decency


Many predicted an ethical storm brewing in the lead-up to the explosion of for-profit interest in psychedelic pharmaceuticals. But, were their efforts to mitigate the damage enough to make a difference?

Eleusis Benefit Corp: Taking the “Psychedelic” Out of Psychedelics


Shlomi Raz, CEO of Eleusis Benefit Corporation, made false claims about psychedelics. We asked multiple ethnobotanists, a medical anthropologist, and a chemist if they could help us set the record straight.

Could wearable microdosing technology be a thing one day?


Could a liquid-delivery system meant to help maintain a personalized “scent bubble” quietly usher in the creation of wearable psychedelic microdosing technology? A U.S. patent for this system is just one among an increasing list of psychedelic-inspired intellectual properties.

BBC Duped into Promoting Marketing Scheme for Microdosing Psychedelics


A recent BBC story entitled “The ‘psychedelics coach’ with drug-fuelled career advice,” offers an opportunity to examine what happens when sloppy journalism and self-promotional psychedelic marketers collide.

What the heck happened to Reality Sandwich?


Reality Sandwich was sold to a group called Delic Corp. Now there's a lawsuit.

An open letter to the newly founded Center for Psychedelic Research at Johns Hopkins


With the recent creation of the Center for Psychedelic and Consciousness Research at Johns Hopkins Medicine in Baltimore, Maryland, we must remember that, while industrialized medicine has never attempted to serve all people, institutional histories vary from one organization to the next.

This is what psychedelic mainstreaming looks like…in Arizona


As psychedelic medicalization and the potential profits of a “virgin market” loom large, new organizations are increasingly looking to gain legitimacy within the field. Mainstreaming means the doors of this field are being thrown wide open.

It’s time to debunk prohibitionist narratives and calls for monopolies within psychedelic science


As venture-capital-backed, for-profit companies barrel into psychedelic therapy, the potential for the widespread privatization of psychedelic knowledge and profits looms large. Some researchers are so enthusiastic about medicalization by “any means necessary” that they’re resorting to prohibitionist historical narratives and calling for monopolies to push the agenda forward.

Corporadelic

A six-part series on the intersection of psychedelics and capitalism, and the early investors making it happen.

Read the series

Corporadelic

A six-part series on the intersection of psychedelics and capitalism, and the early investors making it happen.

Read the series

cor-por-ra-del-ic (adj): manifesting corporate structures, ethos, or logic within the context of the psychedelic landscape.

cor-por-ra-de-lia (n.): the world of people, phenomena, or items associated with corporadelic entities.

The term “corporadelic” was initially coined independently and simultaneously by Dr. Katherine MacLean (a former lead researcher and session guide for psilocybin research at Johns Hopkins University School of Medicine) and Brett Greene (co-founder emeritus of Psymposia and founder of psychedelic pharmaceutical company, Adelia Therapeutics) in 2019. Dr. MacLean defined the term as, “manifesting corporations to commodify psychedelic experiences.”

Amidst Pandemic, Psychedelic Investor Christian Angermayer Can’t Imagine Life Beyond Capitalism


As the coronavirus pandemic rages on, Christian Angermayer, the world’s largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences, calls to sacrifice public health for the sake of “the economy.”

“Flattening The Curve is Complete BS”: Pandemic Advice From Psychedelic Investor Christian Angermayer


In response to the coronavirus pandemic, Christian Angermayer—the world's largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences—dismisses medical experts in his desperation to reboot the economy.

Dear Psychedelic Researchers


The coronavirus has made it clear that psychedelic medicalization will not revolutionize mental healthcare without systemic socioeconomic change.

Calm Down. What’s the Worst Thing That the Wellness Industry Could Do to Psychedelics?


As technology and psychedelics turn to mental health, we’ll likely see a future where we are treated based on our digital biomarkers, and sold mental health services based on the personal data we surrender.

Talking Psychedelic Capitalism in a WeWork Ballroom


Psychedelic capitalists justify their decision to go for-profit in the ballroom of America’s most recent for-profit flop.

Christian Angermayer’s ATAI Life Sciences is positioned to take the psychedelic throne from MAPS


After decades of psychedelic nonprofits paving regulatory pathways and priming wealthy investors, for-profits are moving in to reap the rewards.

“Making psychedelics boring again”— Unless you’re a privileged psychedelic executive, of course


The new leaders of the psychedelic medicalization industry seem to see themselves as above their own self-proposed rules.

Psychedelic Trade Secrets and Get-Rich-Quick Schemes —a Benefit to Investors, a Harm to Progress


“Play the field right and there’s money to be made even off some of the shit companies purely based on the wave.”

Never Forget: Before There Was A Mush Rush, There Was A Plea For Decency


Many predicted an ethical storm brewing in the lead-up to the explosion of for-profit interest in psychedelic pharmaceuticals. But, were their efforts to mitigate the damage enough to make a difference?

Eleusis Benefit Corp: Taking the “Psychedelic” Out of Psychedelics


Shlomi Raz, CEO of Eleusis Benefit Corporation, made false claims about psychedelics. We asked multiple ethnobotanists, a medical anthropologist, and a chemist if they could help us set the record straight.

Could wearable microdosing technology be a thing one day?


Could a liquid-delivery system meant to help maintain a personalized “scent bubble” quietly usher in the creation of wearable psychedelic microdosing technology? A U.S. patent for this system is just one among an increasing list of psychedelic-inspired intellectual properties.

BBC Duped into Promoting Marketing Scheme for Microdosing Psychedelics


A recent BBC story entitled “The ‘psychedelics coach’ with drug-fuelled career advice,” offers an opportunity to examine what happens when sloppy journalism and self-promotional psychedelic marketers collide.

What the heck happened to Reality Sandwich?


Reality Sandwich was sold to a group called Delic Corp. Now there's a lawsuit.

An open letter to the newly founded Center for Psychedelic Research at Johns Hopkins


With the recent creation of the Center for Psychedelic and Consciousness Research at Johns Hopkins Medicine in Baltimore, Maryland, we must remember that, while industrialized medicine has never attempted to serve all people, institutional histories vary from one organization to the next.

This is what psychedelic mainstreaming looks like…in Arizona


As psychedelic medicalization and the potential profits of a “virgin market” loom large, new organizations are increasingly looking to gain legitimacy within the field. Mainstreaming means the doors of this field are being thrown wide open.

It’s time to debunk prohibitionist narratives and calls for monopolies within psychedelic science


As venture-capital-backed, for-profit companies barrel into psychedelic therapy, the potential for the widespread privatization of psychedelic knowledge and profits looms large. Some researchers are so enthusiastic about medicalization by “any means necessary” that they’re resorting to prohibitionist historical narratives and calling for monopolies to push the agenda forward.